---
document_datetime: 2024-09-27 13:53:45
document_pages: 11
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/epidyolex-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: epidyolex-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 6.6338106
conversion_datetime: 2025-12-27 17:37:17.921574
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Epidyolex

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                      | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IAIN/0032            | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release | 26/09/2024                          |                                             | SmPC and PL                      |           |
| R/0031               | Renewal of the marketing authorisation.                                                                                    | 30/05/2024                          | 26/07/2024                                  | SmPC, Annex II and PL            |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| II/0028/G           | This was an application for a group of variations. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority   | 14/03/2024   | n/a   |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------------|
| PSUSA/10798 /202306 | Periodic Safety Update EU Single assessment - cannabidiol (for centrally authorised products only)                                                                                                                                                                                                                                                                                                                                                                                             | 11/01/2024   | n/a   | PRAC Recommendation - maintenance |
| IA/0030/G           | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                     | 11/12/2023   | n/a   |                                   |
| II/0029             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                  | 23/11/2023   | n/a   |                                   |

<div style=\"page-break-after: always\"></div>

| II/0025/G   | This was an application for a group of variations. B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.II.d.1.f - Change in the specification parameters and/or limits of the finished product - Deletion of a specification parameter which may have a significant effect on the overall quality of the finished product A.7 - Administrative change - Deletion of                                                                                  | 01/06/2023   | n/a        |                        | manufacturing sites   |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-----------------------|
| T/0026      | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                        | 15/05/2023   | 31/05/2023 | SmPC, Labelling and PL |                       |
| II/0020     | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                                                                                                                                                                                                                                                             | 26/04/2023   | 05/04/2024 | SmPC and PL            |                       |
|             | This was an application for a group of variations. B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where | 21/02/2023   | n/a        |                        | IB/0024/G             |

<div style=\"page-break-after: always\"></div>

|                     | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.c.1.a - Change in immediate packaging of the AS - Qualitative and/or quantitative composition B.I.b.z - Change in control of the AS - Other variation B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.3.b - Change in batch size (including batch size ranges) of AS or intermediate - Downscaling down to 10-fold   |            |            |                        |                                                                                                                                  |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------|
| IB/0023             | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                                                                                                                                                                                                                                                                                                                                                                                                                                          | 02/02/2023 | 31/05/2023 | SmPC, Labelling and PL | Product information updated to add a new pack-size of 3 100 ml bottles for Epidyolex 100 mg/ml oral solution (EU/1/19/1389/002). |
| PSUSA/10798 /202206 | Periodic Safety Update EU Single assessment - cannabidiol (for centrally authorised products only)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 12/01/2023 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                |
| N/0021              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 22/09/2022 | 31/05/2023 | PL                     |                                                                                                                                  |
| IB/0019             | B.z - Quality Change - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 19/04/2022 | n/a        |                        |                                                                                                                                  |
| IB/0018/G           | This was an application for a group of variations. B.I.b.1.c - Change in the specification parameters                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 21/02/2022 | n/a        |                        |                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.b.1.c - Change in and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.a.4.z - Change to applied during the manufacture variation B.I.a.4.c - Change to applied during the manufacture of a non-significant in-process B.I.a.4.b - Change to applied during the manufacture of a new in-process test B.I.a.3.a - Change in ranges) of AS or intermediate increase compared to size B.I.a.2.z - Changes in the AS - Other variation B.I.a.1.f - Change in starting material/reagent/intermediate Changes to quality control the AS -replacement batch control/testing B.I.a.1.z - Change in starting material/reagent/intermediate   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| II/0016             | Update of section 5.3 of the SmPC to reflect the conclusions of the study GWTX1504, 104 week oral (gavage) administration carcinogenicity study in mouse. For more information, please refer to the Summary of Product Characteristics. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   | 27/01/2022   | 29/06/2022   | SmPC   | Update of section 5.3 of the SmPC to reflect the conclusions of the study GWTX1504, 104 week oral (gavage) administration carcinogenicity study in mouse.                                                                                                                                                                                                                                                                                                                                                                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0015             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                           | 27/01/2022   | 29/06/2022   | SmPC   | Update of sections 4.5 and 5.2 of the SmPC to add drug- drug interaction information with everolimus and P-gp substrates following the assessment the study GWCP19195, a phase I open-label pharmacokinetic drug-drug interaction trial to investigate the effect of cannabidiol on the pharmacokinetics of everolimus in healthy subject. In addition, the MAH took the opportunity to introduce editorial updates in section 5.1 and section 4.9 and to update the local representative contact details of France in the Package Leaflet. |
| PSUSA/10798 /202106 | Periodic Safety Update EU Single assessment - cannabidiol (for centrally authorised products only)                                                                                                                                                                                                                                                          | 13/01/2022   | n/a          |        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| II/0014/G           | This was an application for a group of variations. B.II.d.1.f - Change in the specification parameters and/or limits of the finished product - Deletion of a specification parameter which may have a significant effect on the overall quality of the finished product                                                                                     | 14/10/2021   | n/a          |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|                     | B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |             |                                                                                  |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------|
| PSUSA/10798 /202012 | Periodic Safety Update EU Single assessment - cannabidiol (for centrally authorised products only)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 08/07/2021 | n/a        |             | PRAC Recommendation - maintenance                                                |
| II/0007             | Update of sections 4.2 and 6.6 of the SmPC in order to add information regarding enteral administration using nasogastric and gastrostomy tubes. The Package Leaflet is updated accordingly. In addition, the marketing authorisation holder has taken the opportunity to update the list of local representatives in the PL and implement minor editorial changes. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                    | 24/06/2021 | 29/06/2022 | SmPC and PL |                                                                                  |
| II/0005             | Extension of Indication for use as adjunctive therapy of seizures associated with tuberous sclerosis complex (TSC) for patients 2 years of age and older. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated accordingly. The updated RMP version 2.0 is agreed. The MAH also took the opportunity to correct typographic errors and implement editorial updates as well as implement the updated ethanol statement in compliance with the EC Guideline on Excipient. In addition, the list of local representatives in the PL | 25/02/2021 | 16/04/2021 | SmPC and PL | Please refer to Scientific Discussion 'Product Name-H-C- Product Number-II-0005' |

<div style=\"page-break-after: always\"></div>

|           | representative(s) of Sweden. The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP). C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                                                                                                   |            |            |                 |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|
| IA/0012/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                    | 17/02/2021 | 16/04/2021 | Annex II and PL |
| IB/0011/G | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits | 05/02/2021 | n/a        |                 |

<div style=\"page-break-after: always\"></div>

| IB/0010             | B.II.f.1.b.2 - Stability of FP - Extension of the shelf life of the finished product - After first opening (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 01/02/2021   | 16/04/2021   | SmPC, Labelling and PL   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10798 /202006 | Periodic Safety Update EU Single assessment - cannabidiol (for centrally authorised products only)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 14/01/2021   | n/a          |                          | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0008/G           | This was an application for a group of variations. Update of section 4.5 of the SmPC to reflect the data of the rifampicin drug-drug interaction study GWEP17074. Update of section 4.5 of the SmPC to reflect the data of the CYP1A2 substrate (caffeine) drug-drug interaction study GWCP18056. Update of section 4.5 and 5.2 of the SmPC to propose an additional statement regarding the stiripentol interaction based on the pharmacological study GWEP1447 (provided in eCTD sequence 018, P46 006). Update of section 5.2 of the SmPC to reflect the data of the pharmacokinetic study GWEP17076, exploring the impact of meal, milk and alcohol on cannabidiol exposure. In addition, the MAH took the opportunity to correct the MAH address in the SmPC. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to | 23/07/2020   | 09/12/2020   | SmPC                     | Following the drug-drug interaction study GWEP17074 with rifampicin (CYP3A4 Inducer), section 4.5 of the SmPC has been updated to reflect the decrease plasma concentrations of cannabidiol and 7-hydroxy-cannabidiol by approximately 30 and 60% respectively and potential impact on effectiveness. Following the pharmacokinetic study GWEP17076, section 5.2 of the SmPC has been updated to reflect the effect of low-fat/low-calorie meal, bovine milk and alcohol on cannabidiol exposure. Following the drug-drug interaction study GWCP18056 with caffeine (CYP1A2 Substrate), section 4.5 of the SmPC has been updated to reflect the observed increased in caffeine exposure and recommend the monitoring of patients. Following the drug-drug interaction study GWEP1447 with stiripentol and valproate, the statement in section 4.5 of the SmPC has been adjusted to reflect the data. For more information, please refer to the Summary of Product Characteristics |

<div style=\"page-break-after: always\"></div>

|                     | data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                 |            |            |                       |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-----------------------------------|
| PSUSA/10798 /201912 | Periodic Safety Update EU Single assessment - cannabidiol (for centrally authorised products only)                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 09/07/2020 | n/a        |                       | PRAC Recommendation - maintenance |
| IA/0006             | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                      | 11/05/2020 | n/a        |                       |                                   |
| IB/0003/G           | This was an application for a group of variations. B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size | 25/03/2020 | n/a        |                       |                                   |
| IAIN/0002/G         | This was an application for a group of variations. B.II.b.2.c.2 - Change to importer, batch release                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 16/12/2019 | 09/12/2020 | SmPC, Annex II and PL |                                   |

<div style=\"page-break-after: always\"></div>

|             | arrangements and quality control testing of the FP - Including batch control/testing B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |     |      |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|
| IAIN/0001/G | This was an application for a group of variations. B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch | 27/11/2019 | n/a | size |